**Distinct Effects of *APOE* ε2 on Aβ in Alzheimer- and Vascular-Type Cognitive Impairment**

Jin San Lee, MD, PhD,1-3 Hyejoo Lee, PhD,1,2\* Seongbeom Park, MS,1,2 Yeongsim Choe, BA,1,2 Yu Hyun Park, BA,1,2 Bo Kyoung Cheon, MS,1,2 Alice Hahn, MS,1,2 Rik Ossenkoppele, PhD,4 Hee Jin Kim, MD, PhD,1,2 Seonwoo Kim, PhD,5 Heejin Yoo, MS,5 Hyemin Jang, MD,1,2 Soo Hyun Cho, MD,PhD,6 Seung Joo Kim, MD,7 Jun Pyo Kim, MD,1,2 Young Hee Jung, MD,8 Key-Chung Park, MD, PhD,3 Charles DeCarli, MD, PhD,9 Michael W. Weiner, MD, PhD,10,11 Duk L. Na, MD, PhD,1,2,12 Sang Won Seo, MD, PhD1,2,13-16\*

1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea

2Neuroscience Center, Samsung Medical Center, Seoul 06351, Korea

3Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Korea

4Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands

5Statistics and Data Center, Samsung Medical Center, Seoul, Korea

6Department of Neurology, Chonnam National University Medical School, Gwangju, Korea

7Department of Neurology, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Korea

8Department of Neurology, Myungji Hospital, Goyang, Korea

9Department of Neurology and Center for Neuroscience, University of California, Davis, CA, USA

10Department of Medicine, University of California, 11Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA

12Stem Cell & Regenerative Medicine Institute, 13Samsung Alzheimer Research Center, and 14Center for Clinical Epidemiology, Samsung Medical Center, Seoul 06351, Korea

15Department of Health Sciences and Technology, and 16Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul 06351, Korea

\* These authors contributed equally to the manuscript.

**Corresponding authors**

Sang Won Seo, MD, PhD

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Kangnam-ku, Seoul 06351, Korea

Tel: +82-2-3410-1233, Fax: +82-2-3410-0052, E-mail address: sangwonseo@empal.com

Hyejoo Lee, PhD

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Kangnam-ku, Seoul 06351, Korea

Tel: +82-2-3410-1233, Fax: +82-2-3410-0052, E-mail address: hyejoo271@gmail.com

**Supplemental Data:** Additional Methods, Table e-1, and Table e-2

**Additional Methods**

The selected cerebral cortical VOIs included the following regions: bilateral frontal (superior and middle frontal gyri, the medial part of the superior frontal gyrus, opercular part of the inferior frontal gyrus, triangular part of the inferior frontal gyrus, supplementary motor area, orbital part of the superior, middle, and inferior orbital frontal gyri, rectus and olfactory cortex); posterior cingulate gyri; parietal (superior and inferior parietal lobules, supramarginal and angular gyri, and precuneus); lateral temporal (superior, middle, and inferior temporal gyri, and Heschl gyri); and occipital (superior, middle, and inferior occipital gyri, cuneus, calcarine fissure, and lingual and fusiform gyri).

**Table e-1** LCA results of AIC and BIC values for k = 1 to k = 5

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **One class** | **Two classes** | **Three classes** | **Four classes** | **Five classes** |
| **AIC** | 7439.7 | 7173.0 | 7167.1 | 7172.5 | 7183.8 |
| **BIC** | 7465.7 | 7292.4 | 7255.4 | 7229.6 | 7334.4 |

Abbreviations: LCA = latent cluster class analysis; AIC: Akaike information criterion; BIC: Bayesian information criterion.

**Table e-2** Prevalence estimates of Aβ positivity according to age and *APOE* genotype in the SVCI and ADCI groups

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **SVCI, % (95% CI)** |  | **ADCI, % (95% CI)** |
| **Age, years** |  | **ε3/ε3** | **ε2 carriers** | **ε4 carriers** |  | **ε3/ε3** | **ε2 carriers** | **ε4 carriers** |
| **50** |  | 2.9 (0.9–8.8) | 6.6 (2.0–20.1) | 11.0 (3.7–28.2) |  | 57.8 (48.9–66.2) | 38.4 (24.1–54.9) | 87.5 (82.3–91.3) |
| **55** |  | 4.5 (1.7–11.1) | 10.0 (3.5–25.1) | 16.2 (6.8–33.8) |  | 56.2 (48.9–63.2) | 36.8 (23.6–52.3) | 86.7 (82.2–90.2) |
| **60** |  | 6.8 (3.2–13.9) | 14.8 (6.2–31.1) | 23.2 (12.0–40.1) |  | 54.5 (48.7–60.2) | 35.2 (22.9–49.9) | 85.9 (81.9–89.2) |
| **65** |  | 10.3 (5.8–17.4) | 21.3 (10.5–38.4) | 32.1 (19.9–47.2) |  | 52.8 (48.1–57.5) | 33.7 (22.1–47.8) | 85.1 (81.4–88.1) |
| **70** |  | 15.2 (10.2–22.1) | 29.8 (16.7–47.2) | 42.5 (30.6–55.3) |  | 51.1 (46.9–55.3) | 32.2 (21.1–45.8) | 84.2 (80.6–87.3) |
| **75** |  | 21.9 (16.4–28.5) | 39.9 (24.6–57.4) | 53.6 (42.3–64.5) |  | 49.4 (44.9–54.0) | 30.8 (20.0–44.2) | 83.3 (79.3–86.6) |
| **80** |  | 30.5 (23.6–38.4) | 50.9 (33.3–68.3) | 64.4 (52.8–74.5) |  | 47.8 (42.2–53.3) | 29.4 (18.8–42.8) | 82.3 (77.7–86.2) |
| **85** |  | 40.7 (30.3–52.0) | 61.9 (42.1–78.4) | 73.9 (61.3–83.5) |  | 46.1 (39.2–53.1) | 28.0 (17.5–41.6) | 81.3 (75.7–85.9) |
| **90** |  | 51.8 (36.8–66.4) | 71.7 (50.4–86.4) | 81.6 (68.2–90.1) |  | 44.4 (36.1–53.0) | 26.6 (16.1–40.7) | 80.3 (73.3–85.8) |

The prevalence estimates of Aβ positivity according to *APOE* genotype were generated from logistic regression analyses after adjusting for age (continuous) and *APOE* genotype (ε2 carriers, ε3 homozygotes, and ε4 carriers). The number of participants (ε2 carriers/ε3 homozygotes/ε4 carriers) for modeling in the 50s/60s/70s/80s/90s age range was 8 (0/5/3)/50 (6/35/9)/160 (19/95/46)/89 (7/56/26)/3 (2/1/0) in the SVCI group and 149 (5/81/63)/307 (15/150/142)/390 (23/175/192)/150 (11/93/46)/3 (0/3/0) in the ADCI group, respectively.

Abbreviations: Aβ = amyloid–β; *APOE* = apolipoprotein E; SVCI = subcortical vascular cognitive impairment; ADCI = Alzheimer’s disease-related cognitive impairment.